Collectively, these findings suggest that integrating OX40 co-stimulation into CAR-T platforms provides a versatile and promising avenue to enhance therapeutic outcomes across diverse tumor types, warranting further exploration in preclinical and clinical settings. Here, TNFRSF4 is linked to neoplasm.